Repligen Corp Files 8-K on Financials

Ticker: RGEN · Form: 8-K · Filed: Nov 12, 2024 · CIK: 730272

Repligen Corp 8-K Filing Summary
FieldDetail
CompanyRepligen Corp (RGEN)
Form Type8-K
Filed DateNov 12, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: financial-results, operations, sec-filing

TL;DR

Repligen filed an 8-K on Nov 12, 2024, detailing financial results and operations.

AI Summary

Repligen Corporation filed an 8-K on November 12, 2024, to report on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company is incorporated in Delaware and headquartered in Waltham, MA.

Why It Matters

This filing provides crucial updates on Repligen's financial performance and operational status, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine filing reporting financial results and operations, not indicating any immediate or significant new risks.

Key Players & Entities

  • REPLIGEN CORP (company) — Registrant
  • 41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 (location) — Principal executive offices address
  • November 12, 2024 (date) — Date of earliest event reported

FAQ

What is the primary purpose of this 8-K filing by Repligen Corporation?

The primary purpose of this 8-K filing is to report on Repligen Corporation's results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on November 12, 2024.

What is Repligen Corporation's state of incorporation and principal executive office location?

Repligen Corporation is incorporated in Delaware and its principal executive offices are located at 41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453.

What is the SIC code for Repligen Corporation?

The Standard Industrial Classification (SIC) code for Repligen Corporation is 2836, which corresponds to Biological Products (No Diagnostic Substances).

What is the registrant's telephone number?

The registrant's telephone number is (781) 250-0111.

Filing Stats: 974 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-11-12 07:44:02

Key Financial Figures

  • $0.01 — ich registered Common Stock, par value $0.01 per share RGEN The Nasdaq Global Se

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release by Repligen Corporation, dated November 12, 2024. 99.2 Supplemental Slides issued by Repligen Corporation, dated November 12, 2024 (furnished herewith). 104 Cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Date: November 12, 2024 By: /s/ Olivier Loeillot Olivier Loeillot President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.